Search Videos and More

Showing 1 - 12 of 106 results

Previous| 1 | 2 | 3 ...9 |Next


Dana Farber/Boston Children’s Researchers Uncover Distinct Tumor “neighborhoods” with Each Cell Subtype Playing a Specific Role, in Aggressive Childhood Brain Cancer News

Dana Farber/Boston Children’s Researchers Uncover Distinct Tumor “neighborhoods” with Each Cell Subtype Playing a Specific Role, in Aggressive Childhood Brain Cancer

Their detailed blueprint of tumor cell diversity could guide more precise, targeted treatments for supratentorial ependymomas 
When Small Cell Lung Cancer Hides from Immune Cells, Blood Vessels May Hold the Key News

When Small Cell Lung Cancer Hides from Immune Cells, Blood Vessels May Hold the Key

Researchers at Dana-Farber Cancer Institute have uncovered why small cell lung cancer (SCLC) can stay largely out of reach of the immune system, even when the cancer cells themselves are vulnerable to immune attack.
The Gene Fixer News

The Gene Fixer

For five decades, Stuart Orkin has harnessed new genetic tools to transform care for blood disorders – helping make sickle cell and beta thalassemia curable.
Dana-Farber Research Uncovers Approach to Activating the Immune System Against Metastatic Breast Cancer News

Dana-Farber Research Uncovers Approach to Activating the Immune System Against Metastatic Breast Cancer

Cancer spreads, or metastasizes, when tumor cells shed from a primary solid tumor, for example in the breast, and embed in other organs, such as the lung, liver, and brain, and begin to grow.
Researcher Gains Insight into Rare Genetic Diseases News

Researcher Gains Insight into Rare Genetic Diseases

Rare genetic cancers may affect few people, but their complexity makes them powerful windows into how even the most common cancers develop and behave. 
Dana-Farber, Gustave Roussy to Host Fifth Transatlantic Exchange in Oncology Focused on Cancer Drug Innovation News

Dana-Farber, Gustave Roussy to Host Fifth Transatlantic Exchange in Oncology Focused on Cancer Drug Innovation

Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on Friday, March 27, 2026, bringing together leading cancer researchers and clinicians from the United States and Europe to explore transatlantic innovations in cancer drug research.
Making Breakthroughs in ALL From Youth to Adulthood News

Making Breakthroughs in ALL From Youth to Adulthood

When Ann Carroll was diagnosed with cancer at age 28, her dream to get married and have a baby felt out of reach. Now, seven years later and cancer-free, she is living that dream with her husband and their 7-month-old son, Teddy.  
Cell-Death Safety Net a Potential New Cancer Target News

Cell-Death Safety Net a Potential New Cancer Target

In the rare event that an elevator cable breaks, modern buildings have additional fail-safe mechanisms. For example, counterweight and mechanical brakes prevent the car from plummeting to the ground.  
Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma News

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients
Three Dana-Farber Cancer Institute scientific leaders elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026 News

Three Dana-Farber Cancer Institute scientific leaders elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026

Dr. Alice Shaw, Dr. Kimberly Stegmaier and Dr. Matthew Vander Heiden have been elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026.
Taming Chronic Inflammation News

Taming Chronic Inflammation

Dana-Farber researchers explore how lifestyle choices may help reduce cancer risk and improve outcomes
Addition of CDK 4/6 inhibitor benefits patients with HR+, HER2+ metastatic breast cancer, new study shows News

Addition of CDK 4/6 inhibitor benefits patients with HR+, HER2+ metastatic breast cancer, new study shows

The addition of a CDK 4/6 inhibitor to standard therapy in patients with “double-positive” metastatic breast cancer significantly extended the time the disease did not progress according to data published today in the New England Journal of Medicine.

Showing 1 - 12 of 106 results

Previous| 1 | 2 | 3 ...9 |Next